ResMed AirCurve 11 VAUTO Mode D'emploi page 4

Welcome
The AirCurve 11™ VAuto and AirCurve 11 S are bilevel positive airway pressure devices. The AirCurve 11
ASV is a positive airway pressure device that belongs to the adaptive servo-ventilator category.
WARNING
•
Read this entire guide before using the device.
•
This device is not suitable for ventilator-dependent patients.
•
Before putting patients on ASV, each patient should be assessed for heart failure. In case of signs
and symptoms of heart failure an objective assessment of Left Ventricular Ejection Fraction
(LVEF) should be performed.
CAUTION
In the US, Federal law restricts this device to sale by or on the order of a physician.
Indications for use
AirCurve 11 VAuto
The AirCurve 11 VAuto system is indicated for the treatment of Obstructive Sleep Apnea (OSA) in patients
weighing more than 66 lb (30 kg). The AirCurve 11 VAuto system is intended for use in the hospital and
home.
AirCurve 11 S
The AirCurve 11 S system is indicated for the treatment of Obstructive Sleep Apnea (OSA) in patients
weighing more than 66 lb (30 kg). The AirCurve 11 S system is intended for use in the hospital and home.
AirCurve 11 ASV
The AirCurve 11 ASV system is indicated for the treatment of Obstructive Sleep Apnea (OSA) in patients
weighing more than 66 lb (30 kg). ASV and ASVAuto modes are also indicated for the treatment of central
and/or mixed apneas, or periodic breathing. The AirCurve 11 ASV system is intended for use in the hospital
and home.
Hypoallergenic filter
The hypoallergenic filter provides air filtration during PAP (Positive Airway Pressure) therapy.
HumidAir 11
The HumidAir 11 enables the provision of humidification. It is intended for home and hospital use.
Contraindications
Positive airway pressure therapy may be contraindicated in some patients with the following pre-existing
conditions:
•
severe bullous lung disease
•
pneumothorax or pneumomediastinum
•
pathologically low blood pressure, particularly if associated with intravascular volume depletion
•
dehydration
•
cerebrospinal fluid leak, recent cranial surgery, or trauma.
ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced
left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnea.
Adverse effects
You should report unusual chest pain, severe headache, or increased breathlessness to your prescribing
physician. An acute upper respiratory tract infection may require temporary discontinuation of treatment.
The following side effects may arise during the course of therapy with the device:
•
drying of the nose, mouth, or throat
•
nosebleed
•
bloating
English 1